BR112016007016A2 - composto ou um sal farmaceuticamente aceitável do mesmo, método para tratamento sintomático do comprometimento cognitivo na demência, e, composição farmacêutica - Google Patents

composto ou um sal farmaceuticamente aceitável do mesmo, método para tratamento sintomático do comprometimento cognitivo na demência, e, composição farmacêutica

Info

Publication number
BR112016007016A2
BR112016007016A2 BR112016007016A BR112016007016A BR112016007016A2 BR 112016007016 A2 BR112016007016 A2 BR 112016007016A2 BR 112016007016 A BR112016007016 A BR 112016007016A BR 112016007016 A BR112016007016 A BR 112016007016A BR 112016007016 A2 BR112016007016 A2 BR 112016007016A2
Authority
BR
Brazil
Prior art keywords
dementia
pharmaceutical composition
symptomatic treatment
compound
pharmaceutically acceptable
Prior art date
Application number
BR112016007016A
Other languages
English (en)
Other versions
BR112016007016A8 (pt
Inventor
Khan Afzal
James BRAUNTON Alan
Payne Andrew
Edward Kitulagoda James
Luis Castro Pineiro Jose
Michelle Birch Louise
Soejima Motohiro
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of BR112016007016A2 publication Critical patent/BR112016007016A2/pt
Publication of BR112016007016A8 publication Critical patent/BR112016007016A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

derivados de 4-azaindol que são moduladores do receptor muscarínico de acetilcolina (machr) m1 e que podem ser eficazes para a prevenção ou modificação de doença ou tratamento sintomático de déficits cognitivos associados com distúrbios neurológicos, tais como demência do tipo alzheimer (ad) ou demência com corpos de lewy (dcl) e uma composição farmacêutica compreendendo um derivado de 4-azaindol como um ingrediente ativo.
BR112016007016A 2013-10-01 2014-09-30 composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto, e, composição farmacêutica BR112016007016A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1317363.8A GB201317363D0 (en) 2013-10-01 2013-10-01 Novel compounds
PCT/IB2014/001978 WO2015049574A1 (en) 2013-10-01 2014-09-30 4-azaindole derivatives

Publications (2)

Publication Number Publication Date
BR112016007016A2 true BR112016007016A2 (pt) 2017-08-01
BR112016007016A8 BR112016007016A8 (pt) 2020-02-27

Family

ID=49585123

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007016A BR112016007016A8 (pt) 2013-10-01 2014-09-30 composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto, e, composição farmacêutica

Country Status (21)

Country Link
US (3) US20150094328A1 (pt)
EP (2) EP3489237B1 (pt)
JP (3) JP6517790B2 (pt)
KR (1) KR102248559B1 (pt)
CN (1) CN105873927B (pt)
AR (1) AR097866A1 (pt)
AU (1) AU2014330880B2 (pt)
BR (1) BR112016007016A8 (pt)
CA (1) CA2924619C (pt)
CL (1) CL2016000726A1 (pt)
ES (2) ES2710190T3 (pt)
GB (1) GB201317363D0 (pt)
HK (1) HK1223090A1 (pt)
IL (1) IL244609B (pt)
MX (1) MX368956B (pt)
PE (1) PE20160839A1 (pt)
PH (1) PH12016500529A1 (pt)
RU (1) RU2688938C2 (pt)
SG (1) SG11201602052YA (pt)
TW (1) TW201546070A (pt)
WO (1) WO2015049574A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
AU2015250610B2 (en) 2014-04-23 2019-02-07 Takeda Pharmaceutical Company Limited Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease
US10208046B2 (en) 2014-05-16 2019-02-19 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
ME03379B (me) * 2015-06-08 2020-01-20 Suven Life Sciences Ltd Pozitivni alosterni modulatori muskarinskog m1 receptora
LT3347349T (lt) 2015-09-10 2019-12-10 Suven Life Sciences Ltd Fluorindolo dariniai kaip muskarininio m1 receptoriaus teigiami alosteriniai moduliatoriai
KR20180110132A (ko) * 2016-02-16 2018-10-08 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제
US10899759B2 (en) 2016-09-30 2021-01-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
SG11202003284RA (en) * 2017-10-18 2020-05-28 Suven Life Sciences Ltd Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
WO2019082140A1 (en) * 2017-10-27 2019-05-02 Suven Life Sciences Limited POLYCYCLIC AMIDES AS POSITIVE ALLOSTERIC MODULATORS OF M1 MUSCARINIC RECEPTOR
KR102347368B1 (ko) * 2020-11-03 2022-01-07 (주)케이메디켐 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
MXPA04004711A (es) 2001-11-19 2005-08-16 Neurogen Corp Amidas del acido 1h-pirrolo(3,2-b(piridin-3-carboxilico.
GB0222743D0 (en) 2002-10-01 2002-11-06 Celltech R&D Ltd Chemical compounds
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
WO2006092430A1 (de) 2005-03-03 2006-09-08 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
FR2890072A1 (fr) * 2005-09-01 2007-03-02 Fournier S A Sa Lab Nouveaux composesde pyrrolopyridine
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
US7964728B2 (en) 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
JP2010511632A (ja) 2006-11-30 2010-04-15 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼ活性化タンパク質インヒビターおよび一酸化窒素モジュレーターを含んでいる組成物および治療法
WO2009023623A1 (en) 2007-08-10 2009-02-19 H, Lundbeck A/S Heteroaryl amide analogues
CA2697500A1 (en) 2007-08-29 2009-03-12 Schering Corporation 2,3-substituted azaindole derivatives for treating viral infections
WO2009094279A1 (en) 2008-01-25 2009-07-30 Merck & Co., Inc. Quinolizidinone m1 receptor positive allosteric modulators
DK2240482T3 (da) 2008-01-31 2013-10-21 Sanofi Sa Cykliske azaindol-3-carboxamider, deres fremstilling og deres anvendelse som lægemidler
US20110098483A1 (en) 2008-03-27 2011-04-28 University Of Southern California Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof
CA2685716A1 (en) 2008-04-04 2009-10-08 Summit Corporation Plc Compounds for treating muscular dystrophy
US8012992B2 (en) 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
CN102186833A (zh) 2008-08-18 2011-09-14 耶鲁大学 Mif调节剂
WO2010033980A2 (en) 2008-09-22 2010-03-25 Isis Innovation Ltd. 4-azaindole bisphosphonates
MY162502A (en) 2008-11-20 2017-06-15 Merck Sharp & Dohme Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
CN102232076B (zh) 2008-12-05 2014-12-31 霍夫曼-拉罗奇有限公司 吡咯并吡嗪基脲激酶抑制剂
EP2370407B1 (en) 2008-12-19 2014-06-18 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
JP2012518640A (ja) 2009-02-23 2012-08-16 メルク・シャープ・エンド・ドーム・コーポレイション ピラゾロ［４，３−ｃ］シンノリン−３−オンＭ１受容体陽性アロステリックモジュレーター
US8293744B2 (en) 2009-04-20 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline M1 receptor positive allosteric modulators
JP2012211085A (ja) 2009-08-12 2012-11-01 Kyowa Hakko Kirin Co Ltd ヘッジホッグシグナル阻害剤
JP2013503132A (ja) * 2009-08-26 2013-01-31 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング メチルピロロピリジンカルボキサミド
HUE026296T2 (en) 2009-08-31 2016-06-28 Merck Sharp & Dohme Positive allosteric pyranyl arylmethyl benzoquinazolinone M1 receptor modulators
EP2512245B1 (en) 2009-12-14 2014-07-23 Merck Sharp & Dohme Corp. Pyridoquinazolinone m1 receptor positive allosteric modulators
EA022494B1 (ru) * 2009-12-17 2016-01-29 Мерк Шарп Энд Домэ Корп. Соединения хинолинамида в качестве положительных аллостерических модуляторов мускаринового рецептора m1
WO2011084371A1 (en) 2009-12-21 2011-07-14 Merck Sharp & Dohme Corp. Aminobenzoquinazolinone m1 receptor positive allosteric modulators
EP2519520A1 (en) 2009-12-23 2012-11-07 Sanofi [4-(3-aminomethyl-phenyl)-piperidin-1-yl]-(1h-pyrrolopyridinyl)-methanone derivatives as tryptase inhibitors
US8883850B2 (en) 2010-05-28 2014-11-11 Merck Sharp & Dohme Corp. Naphthalene carboxamide M1 receptor positive allosteric modulators
EP2582241B1 (en) * 2010-06-15 2016-04-06 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
US8815902B2 (en) * 2010-06-15 2014-08-26 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide M1 receptor positive allosteric modulators
WO2012003147A1 (en) 2010-07-01 2012-01-05 Merck Sharp & Dohme Corp. Isoindolone m1 receptor positive allosteric modulators
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US8664234B2 (en) 2010-10-04 2014-03-04 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
ES2716865T3 (es) 2011-02-18 2019-06-17 Scripps Research Inst Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012154888A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
WO2012158473A1 (en) 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
EP2709451B1 (en) 2011-05-17 2015-12-30 Merck Sharp & Dohme Corp. N-linked lactam m1 receptor positive allosteric modulators
US8940765B2 (en) 2011-05-17 2015-01-27 Merck Sharp & Dohme Corp. N-linked quinolineamide M1 receptor positive allosteric modulators
EP2770997B1 (en) 2011-10-28 2016-09-14 Vanderbilt University Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1
WO2013091773A1 (en) 2011-12-22 2013-06-27 Merck Patent Gmbh Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
WO2013106795A1 (en) * 2012-01-12 2013-07-18 Vanderbilt University Substituted 4-(1h~pyrazol-4.yl)benzyl analogues as positive allosteric modulators of machr m1 receptors
EP3021947B1 (en) * 2013-07-17 2017-08-23 Global Alliance For Tb Drug Development Azaindole compounds, synthesis thereof, and methods of using the same
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
MX2016001942A (es) * 2013-09-27 2016-06-02 Hoffmann La Roche Derivados de indol e indazol.
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds

Also Published As

Publication number Publication date
PH12016500529A1 (en) 2016-05-16
RU2016116775A (ru) 2017-11-09
CA2924619C (en) 2021-12-07
US10072005B2 (en) 2018-09-11
EP3052496B1 (en) 2018-11-28
EP3052496A1 (en) 2016-08-10
BR112016007016A8 (pt) 2020-02-27
CN105873927A (zh) 2016-08-17
CL2016000726A1 (es) 2016-09-23
JP6899944B2 (ja) 2021-07-07
CA2924619A1 (en) 2015-04-09
JP6517790B2 (ja) 2019-05-22
IL244609A0 (en) 2016-04-21
SG11201602052YA (en) 2016-04-28
RU2016116775A3 (pt) 2018-06-27
MX2016004014A (es) 2016-09-21
KR20160072133A (ko) 2016-06-22
IL244609B (en) 2019-12-31
CN105873927B (zh) 2017-11-28
JP2019112433A (ja) 2019-07-11
US9926312B2 (en) 2018-03-27
HK1223090A1 (zh) 2017-07-21
PE20160839A1 (es) 2016-08-20
ES2807221T3 (es) 2021-02-22
EP3489237B1 (en) 2020-05-13
ES2710190T3 (es) 2019-04-23
US20150094328A1 (en) 2015-04-02
GB201317363D0 (en) 2013-11-13
EP3489237A1 (en) 2019-05-29
JP2016531890A (ja) 2016-10-13
JP2020143100A (ja) 2020-09-10
AU2014330880A1 (en) 2016-04-07
WO2015049574A1 (en) 2015-04-09
AU2014330880B2 (en) 2019-01-31
MX368956B (es) 2019-10-23
KR102248559B1 (ko) 2021-05-04
US20180208593A1 (en) 2018-07-26
TW201546070A (zh) 2015-12-16
AR097866A1 (es) 2016-04-20
US20160244445A1 (en) 2016-08-25
RU2688938C2 (ru) 2019-05-23

Similar Documents

Publication Publication Date Title
BR112016007016A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para tratamento sintomático do comprometimento cognitivo na demência, e, composição farmacêutica
CL2016002661A1 (es) Compuestos derivados de isoindolin-1-ona, con actividad del receptor colinérgico muscarínico m1 del modulador alostérico positivo; composición farmacológica; útiles para el tratamiento del alzheimer, esquizofrenia, dolor, trastornos del sueño, demencia asociada al parkinson o demencia con cuerpos de lewy.
BR112017007662A2 (pt) composto, composição farmacêutica, processo de elaboração de uma composição farmacêutica, método de tratamento de distúrbio ou doença relativa a er, kit de tratamento e uso de composto
BR112018015283A2 (pt) compostos orgânicos
PH12018501731A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
BR112018006121A2 (pt) fármacos antiestrogênicos de tetra-hidro-1h-pirido[3,4-b]indol
CL2012001955A1 (es) Compuestos derivados biciclicos de triazol sustituidos, moduladores de gamma secretasa; composicion farmaceutica que los comprende; utiles en el tratamiento o la prevencion de enfermedad de alzheimer, demencia, demencia asociada con la enfermedad de parkinson, entre otras.
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
CL2012001605A1 (es) Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño.
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
NZ704863A (en) Bicyclic pyridinones useful as gamma secretase modulators
WO2014106238A8 (en) Heterocyclic compounds and methods of use thereof
BR112016015235A2 (pt) Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
CR20180111A (es) Agentes antibacteriales que comprenden una pirazino[2,3-b] [1,4] oxazin-3-ona o un sistema de anillos relacionado
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
BR112016023991A2 (pt) ativadores de herg policíclicos
EP3659584A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISORDERS, CONTAINING HDL-APOM-S1P AS ACTIVE INGREDIENT
BR112018067663A2 (pt) compostos derivados de sulfamato, processos para preparação dos mesmos e seus usos
CO7091183A2 (es) Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiátricos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time